http://www.PR.com/ Latest news releases from PR.com for Lankenau Institute for Medical Research. Tue, 14 Feb 2012 15:48:04 -0500 © 2012 PR Worldwide, Inc. 60 en-us http://www.PR.com/images/logo_white.jpg http://www.PR.com/ 68 69 PR.com provides Free Press Release Distribution, & is a unique Directory of Businesses, Products, Services, & Jobs - in all industries. Find Full Company Profiles. http://www.pr.com/press-release/251370 Wed, 28 Jul 2010 03:00:00 -0400 Seventy-five percent of pancreatic cancer patients die within the first 12 months of their diagnosis. In a collaborative project, George Prendergast, Ph.D., Professor, President & CEO at the Lankenau Institute for Medical Research (LIMR) and Iraimoudi Ayene, Ph.D., Associate Professor at LIMR, received a one-year $125,000 grant from the Elsa U. Pardee Foundation to conduct the research project entitled Novel [PR.com] http://www.pr.com/press-release/251370 Lankenau Institute for Medical Research http://www.pr.com/press-release/249885 Wed, 21 Jul 2010 03:00:00 -0400 Affecting more than 1.3 million people in the United States alone, rheumatoid arthritis (RA) is a debilitating disease that causes pain, swelling, and stiffness in the joints. Dr. Laura Mandik-Nayak, Assistant Professor at the Lankenau Institute for Medical Research (LIMR), received a five-year, $1,856,250 National Institutes of Health (NIH) grant for a research project entitled: IDO in inflammatory pathogenesis and [PR.com] http://www.pr.com/press-release/249885 Lankenau Institute for Medical Research http://www.pr.com/press-release/227349 Fri, 16 Apr 2010 03:00:00 -0400 CureDM, LLC, a biopharmaceutical company with collaborative ties to the Lankenau Institute for Medical Research (LIMR), announced that they have signed an agreement with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. In a collaborative research partnership, LIMR Associate Professor, Lisa-Laury Kleintop, Ph.D., help [PR.com] http://www.pr.com/press-release/227349 Lankenau Institute for Medical Research http://www.pr.com/press-release/191638 Mon, 09 Nov 2009 08:00:00 -0500 Alzheimer’s disease (AD), which afflicts over 5.3 million people in the United States alone, is the most common of over 25 incurable protein misfolding diseases termed amyloidoses. In a paper published in The Journal of Biological Chemistry, Sharad P. Adekar, MD, Scientist at the Lankenau Institute for Medical Research (LIMR) and Scott Dessain, M.D., Ph.D. Associate Professor at LIMR, have discovered a potential new [PR.com] http://www.pr.com/press-release/191638 Lankenau Institute for Medical Research http://www.pr.com/press-release/191380 Sun, 08 Nov 2009 03:00:00 -0500 Immunome, Inc., President and CEO, Tim Pelura, Ph.D., will be presenting information about the company on Monday, November 9, 2009 at the Pharmaceutical Consulting Consortium, Inc. (PCCI) Meeting. The presentation will be also be available for viewing via webcast at www.rxpcci.com. Immunome is a start-up biopharmaceutical company located in the biotechnology incubator at the Lankenau Institute for Medical Research in [PR.com] http://www.pr.com/press-release/191380 Lankenau Institute for Medical Research http://www.pr.com/press-release/169160 Sat, 01 Aug 2009 03:00:00 -0400 Dr. Janet Sawicki, Professor at the Lankenau Institute for Medical Research (LIMR), along with its collaborating institution, the Massachusetts Institute of Technology (MIT), published a paper in Cancer Research whose findings suggest a potential new therapy to treat advanced stage ovarian cancer. [PR.com] http://www.pr.com/press-release/169160 Lankenau Institute for Medical Research http://www.pr.com/press-release/158322 Sat, 13 Jun 2009 03:00:00 -0400 Dr. Mindy George-Weinstein, Professor at the Lankenau Institute for Medical Research (LIMR), in collaboration with Dr. Sue Menko, Professor at Thomas Jefferson University, received a three-year grant in the amount of $264,410 from the March of Dimes to study the development of eye defects that may lead to cataracts, glaucoma, increased sensitivity to light, squinting or blindness in newborns. [PR.com] http://www.pr.com/press-release/158322 Lankenau Institute for Medical Research http://www.pr.com/press-release/147975 Sun, 26 Apr 2009 03:00:00 -0400 The research group of Dr. James Michael Mullin, Professor at the Lankenau Institute for Medical Research (LIMR), is conducting a clinical trial for patients with Crohn’s Disease. Past work of Dr. Mullin’s group has shown that dietary restriction of the amino acid methionine can improve the junctional seals between epithelial cells. This holds the promise that dietary restriction of methionine may be able to improve [PR.com] http://www.pr.com/press-release/147975 Lankenau Institute for Medical Research http://www.pr.com/press-release/137677 Wed, 11 Mar 2009 03:00:00 -0400 The Lankenau Institute for Medical Research (LIMR) and its collaborating institution, the Massachusetts Institute of Technology (MIT), announced on March 9, 2009, that LIMR has been selected by the National Cancer Institute (NCI) for a research collaboration to perform preclinical studies on novel therapeutic nanoparticles for treatment of solid tumors. The research will be conducted by the NCI’s Nanotechnology [PR.com] http://www.pr.com/press-release/137677 Lankenau Institute for Medical Research http://www.pr.com/press-release/131586 Wed, 11 Feb 2009 03:00:00 -0500 Ovarian cancer is the fourth most common cancer in women and has the highest mortality rate for gynecologic cancers because it is often diagnosed at an advanced stage. New effective therapies for the treatment of advanced stage ovarian cancer are urgently needed. A paper published February 9, 2009, in the Proceedings of the National Academy of Sciences (PNAS) by Dr. Janet Sawicki, Professor at the Lankenau Institute for [PR.com] http://www.pr.com/press-release/131586 Lankenau Institute for Medical Research http://www.pr.com/press-release/130366 Thu, 05 Feb 2009 03:00:00 -0500 A team of researchers from CureDM, Inc, in collaboration with the Lankenau Institute for Medical Research (LIMR) reported a ground breaking discovery with the potential to reverse type 1 and type 2 diabetes. In a paper published in Endocrine Practice, the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, these researchers have described the discovery of a human peptide called the [PR.com] http://www.pr.com/press-release/130366 Lankenau Institute for Medical Research http://www.pr.com/press-release/123418 Wed, 24 Dec 2008 03:00:00 -0500 The research group of Dr. James Michael Mullin, Professor at the Lankenau Institute for Medical Research (LIMR), recently co-authored two papers that describe how proton pump inhibitors (PPIs) have been shown to compromise upper gastrointestinal (GI) barrier function. These studies provide new information about an unexpected potentially harmful side effect of taking PPIs. [PR.com] http://www.pr.com/press-release/123418 Lankenau Institute for Medical Research http://www.pr.com/press-release/112990 Sun, 26 Oct 2008 03:00:00 -0400 Many cancers are believed to be caused or accelerated by chronic inflammation, such as skin, lung, colon, and prostate cancers. Genes that connect inflammation and cancer are of great medical interest because they may offer tactics to prevent or treat these diseases. Today, a team of researchers at the Lankenau Institute of Medical Research (LIMR) and the Medical College of Georgia (MCG) report the discovery that a gene [PR.com] http://www.pr.com/press-release/112990 Lankenau Institute for Medical Research http://www.pr.com/press-release/101447 Fri, 22 Aug 2008 03:00:00 -0400 A new paper published in PLoS One, an international, peer-reviewed, open access, online publication by the Public Library of Science, have revealed an additional mechanism to neutralize Botuliimum neurotoxins (BoNTs). BoNTs are a family of toxins that cause the disease botulism, but they can also be used as bioterror agents that cause paralysis when they poison the neurons that transmit the signals responsible for [PR.com] http://www.pr.com/press-release/101447 Lankenau Institute for Medical Research